
Americas Gastrointestinal Drugs Market Share
Americas Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs, and Others), By Route of Administration (Oral, Parenteral, Rectal), By disease type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other), By end user (Hospital Pharmacies, Retail Pharmacies and Other) - Forecast till 2035

Market Summary
The United States of America gastrointestinal drugs market is projected to grow from 12.3 USD billion in 2024 to 19.7 USD billion by 2035.
Key Market Trends & Highlights
Americas Gastrointestinal Drugs Key Trends and Highlights
- The market is expected to experience a compound annual growth rate of 4.34 percent from 2025 to 2035.
- By 2035, the gastrointestinal drugs market in the United States is anticipated to reach a valuation of 19.7 USD billion.
- In 2024, the market is valued at 12.3 USD billion, indicating a robust growth trajectory.
- Growing adoption of innovative treatment options due to increasing prevalence of gastrointestinal disorders is a major market driver.
Market Size & Forecast
2024 Market Size | 12.3 (USD Billion) |
2035 Market Size | 19.7 (USD Billion) |
CAGR (2025-2035) | 4.34% |
Largest Regional Market Share in 2024 | latin_america) |
Major Players
AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories (US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany), Evoke Pharma (US), Valent Pharmaceuticals (US)
Market Trends
Americas Gastrointestinal Drugs Market Market Drivers
Market Segment Insights
Regional Insights
Key Companies in the Americas Gastrointestinal Drugs Market market include





Industry Developments
Market Segmentation
Report Scope
Report Attribute/Metric | Details |
Market Size 2023 | 11.2 (USD Billion) |
Market Size 2024 | 12.34 (USD Billion) |
Market Size 2032 | 16.7 (USD Billion) |
Compound Annual Growth Rate (CAGR) | 9.2 % (2024 - 2032) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Base Year | 2023 |
Market Forecast Period | 2024 - 2032 |
Historical Data | 2019 - 2023 |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | AbbVie Inc. (US), AstraZeneca (UK), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany). Evoke Pharma (US), Valent Pharmaceuticals(US) |
Key Market Opportunities | Increasing cases of conditions like Crohn's disease, ulcerative colitis, and irritable bowel syndrome (IBS) drive demand for effective treatments. |
Key Market Drivers | Increasing incidence of gastrointestinal diseases like GERD, IBS, and Crohn's disease. |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
-
Table of Contents
-
1 INTRODUCTION
- DEFINITION
-
SCOPE OF STUDY
- RESEARCH OBJECTIVE
- ASSUMPTIONS & LIMITATIONS
- MARKET STRUCTURE:
-
2 Research Methodology
- RESEARCH PROCESS:
- PRIMARY RESEARCH
- SECONDARY RESEARCH:
-
3 MARKET DYNAMICS
- DRIVERS
- RESTRAINTS
- OPPORTUNITIES
- MACROECONOMIC INDICATORS
-
4 MARKET FACTOR ANALYSIS
- PORTERS FIVE FORCES MODEL
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF BUYERS
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTES
- INTENSITY OF RIVALRY
-
AMERICAS GASTROINTESTINAL DRUG MARKET, BY DRUG CATEGORY
-
ACID NEUTRALIZERS
- ANTACID
- H2 ANATAGONISTS
- PROTON PUMP INHIBITORS
- OTHERS
- LAXATIVES & ANTIDIARRHEAL
- ANTINFLAMMATORY
- ANTIEMETIC
- OTHER
-
ACID NEUTRALIZERS
-
AMERICAS GASTROINTESTINAL DRUG MARKET, BY ROUTE OF ADMINISTRATION
- ORAL
- PARENTAL
- RECTAL
-
AMERICAS GASTROINTESTINAL DRUG MARKET, BY DISEASES TYPE
- GASTROESPHAGEAL REFLUX DISEASES
-
INFLAMMATORY BOWEL DISEASES
- CHRON’S DISEASE
- ULCERTAVIE COLITIS
- OTHER.
-
AMERICAS GASTROINTESTINAL DRUG MARKET, BY END USERS
- HOSPITAL PHARMACIES
- RETAIL PHARMACIES
- OTHERS
-
AMERICAS GASTROINTESTINAL DRUG MARKET, BY REGION
-
INTRODUCTION
- NORTH AMERICA
- SOUTH AMERICA
-
INTRODUCTION
-
Competitive Landscape
-
MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
- STRATEGIC PARTNERSHIP
- MERGER & ACQUISITION
-
MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
-
11 COMPANY PROFILE
-
ABBVIE INC.
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
ABBOTT LABORATORIES
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
ALLERGEN PLC.
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- STRATEGY
- KEY DEVELOPMENT
-
BAYER AG
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
BOEHRINGER INGELHEIM GMBH
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
GALXOSMITHKLINE
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
JASSEN PHARMACEUTICALS INC
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
ABBVIE INC.
-
8 OTHERS
Americas Gastrointestinal Drugs Market Segmentation
Market Segmentation Overview
- Detailed segmentation data will be available in the full report
- Comprehensive analysis by multiple parameters
- Regional and country-level breakdowns
- Market size forecasts by segment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment